郭翼 主治医师
硕士招生类型：学术型；专业型
硕士招生专业：妇产科学
博士招生类型：
博士招生专业：
所在院系：附属同济医院
联系方式：Guoyi600@sina.com
课题组链接：
研究方向
主要任职
科研业绩

妇科肿瘤 GynecologicalOncology

郭翼，同济大学妇产科学博士，美国宾夕法尼亚大学Perelman医学院联合培养博士，主要研究方向为妇科肿瘤的发病机制及靶向治疗的研究。目前发表的SCI收录论文10余篇，最高影响因子为7.19分，发表国内外大会论文4篇，作为负责人主持国家自然基金1项及院级课题1项，获得上海市青年医师培养资助计划、同济大学青年优秀人才培养资助计划、上海市同济医院后备人才培养计划（甘泉新星）等人才项目。为上海市医学会妇产科分会青年委员。2016年获得同济医院“金教鞭”全英文讲课比赛规培组一等奖，2017年获得同济医院“金教鞭”全英文讲课比赛一等奖。
Yi Guo, PhD, MD,Attending, Department of Obstetrics and Gynecology, Tongji Hospital, TongjiUniversity School of Medicine. Yi Guo pursued her doctor’s degree by joint-supervision ofTongji University and University of Pennsylvania. She is now the member ofYouth Commission of Shanghai Medical Association (OBG division). Her researchfocused on the mechanism of gynecological malignant and its targeted therapy.She has more than 10 publications with the highest impact factor of 7.19. Sheis sponsored by National Nature Science Foundation of China and YouthScientists Grants of Tongji hospital. She is also included in Young ExcellentDoctor Fostering Program of Shanghai, Young Excellent Talents fostering Programof Tongji University, New-Arising Promising Doctors Program of Tongji Hospital.She is the winner in contests of Medical Teaching in English for two years in arow (2016 and 2017). She now participates in education and instruction forinterns.

1. 主持或参加科研项目（课题）及人才计划项目情况：
(5 grants as PI, 2 grants as participant )
1) 2016年同济医院青年项目（TJ1611），主持，课题名称为“TEM1促进子宫肉瘤侵袭、转移的机制研究”，2016-2018；
2) 2017年上海市青年医师资助培养计划”，主持，2017-2020；
3) 2017年同济大学青年优秀人才培养资助计划，主持，2017-2020;
4) 2018年国家自然基金青年项目（**），主持，TEM1介导的MMPs/integrin通路促进子宫肉瘤侵袭转移的机制研究，2019.01-2021.12；
5) 2018年同济医院后备人才培养资助计划“甘泉新星”，主持，2019-2022；
6) 国家十二五科技支撑计划项目，No. 2012BAI17B05，盆底功能修复软组织重建材料的研发，2012.01至2015.12，744.0万，已结题，参加。
7) 上海市科委课题，No.124119a3800，检测高危HPV DNA的整合状态预测宫颈癌变，2012.12.1-2015.12.1, 30万，已结题，参加。
2. 代表性研究成果和学术奖励情况
一、期刊论文
第一及共同第一作者. (Firstand co-first author articles )
1) Y Guo#, J Hu#, Y Wang,X Peng, J Min, J Wang, E Matthaiou, Y Cheng, K Sun, X Tong, Y. Fan, P J Zhang, LE Kandalaft, M Irving f, G Coukos, C Li. Tumour endothelial marker1/endosialin-mediated targeting of human sarcoma. European J Cancer, Volume 90, February 2018, Pages 111–121.
2) Yi Guo#, Kewei Chen#,Ying Zhang#, et al. TEM1 knockdown inhibits proliferation and metastasisin MES-SA uterine sarcoma. Int J Clin Exp Med. 2017;10(9):13133-13142.
3) Guo Y#, Hu J, Zhu L, Sun J,Xie L, Kong F, Han L, Li F*. Physical Status and Variant Analysis of HumanPapillomavirus 16 in Women from Shanghai. Gynecologic and ObstetricInvestigation. 2016;81(1):61-70. doi: 10.1159/.
4) Chen, Yao#; Xu, Mengjiao#; Guo, Yi#; Tu, Keyao; Wu, Weimin;Wang, Jianjun; Tong, Xiaowen; Wu, Wenjuan; Qi*, Lifeng*; Shi, Donglu Targetedchimera delivery to ovarian cancer cells by heterogeneous gold magneticnanoparticle. Nanotechnology. 2016.9. Nanotechnology. 2017Jan 13;28(2):025101.
5) Deng J^#, Guo Y^#, Jiang Z, Yang M, Li H,Wang J*. Enhancement of Ovarian Cancer Chemotherapy by Delivery ofMultidrug-Resistance Gene Small Interfering RNA Using Tumor TargetingSalmonella. The Journal of Obstetrics and Gynaecology Research. J Obstet Gynaecol Res. 2015Apr;41(4):615-22. doi: 10.1111/jog.12598.
非第一非通讯作者文章 (Co-authorarticles)
1) Chunsheng li, Junying Wang, Effthymia Matthaiou, Yi Guo, et al.Immuno-imaging and therapy in ovarian cancer and sarcoma with de novo singlechain fv-fv fusion protein targeting TEM1/CD248. J immunother Cancer,2014; 2(Suppl 3):P219.
2) Zhao JW, Fang F, Guo Y, et al. HPV16integration probably contributes to cervical oncogenesis through interruptingtumor suppressor genes and inducing chromosome instability. J Exp Clin CancerRes. 2016 Nov 25;35(1):180
3) Li F#, Guo Y, Han L, Duan Y, Fang F, Niu S, Ba Q, Zhu H, KongF, Lin C*, Wen X*. In vitro and in vivo growth inhibition of drug-resistantovarian carcinoma cells using a combination of cisplatin and a TRAIL-encodingretrovirus. Oncol Lett. 2012 Dec;4(6):1254-1258.
4) Li #F, Ba Qiujie#, Niu Sumei, Guo Yi, Shi Donglu*. In-situforming biodegradable glycol chitosan-based hydrogels: Synthesis,characterization, and chondrocyte culture. Materials Science and EngineeringC-biomimetic and Supramolecular Systems. 2012.05.021, 2017 - 202510.1016/j.msec.
5) Li F#, Niu S#, Sun J, Zhu H, Ba Q, Guo Y, Shi D*. EfficientIn Vitro TRAIL-Gene Delivery in Drug-Resistant A2780/DDP Ovarian Cancer CellLine via Magnetofection. JOURNAL OF NANOMATERIALS. DOI: 10.1155/2011/484589.
二、 会议论文 (Conferencearticles)
1) Yi Guo, Junying Wang, Jia Hu, XiaohuiPeng, Chunsheng Li. Development of Immunotoxin Targeting TEM1/CD248 forsarcoma. Translational Research Cancer Centers Consortium. Feb18-20, 2015.
2) Yi Guo, Jiaqi Deng, Jianjun Wang.Enhancement of Ovarian Cancer Chemotherapy by Delivery of Multidrug-ResistanceGene Small Interfering RNA Using Tumor Targeting Salmonella. Dec 7-9, 2015,Busan, Korea.
3) Chunsheng Li, Junying Wang, Efthymia Iliana Matthaiou, Yi Guo,et al. Immuno-imaging and -therapy in Ovarian cancer and sarcoma with de novosingle-chain fv-fc fusion protein targetingTEM1/CD248.Journal for ImmunoTherapyof Cancer 2014, 2(Suppl 3): P219. From Society for Immunotherapy of Cancer 29thAnnual Meeting National Harbor,MD, USA. 6-9 November 2014.